Neurosona Wins Award at Korea Invention Patent Exhibition

Neurosona, a specialized company developing low-intensity focused ultrasound (Low-Intensity Focused Ultrasound) electronic medicine for brain disease treatment, announced on the 2nd that it won the Minister of Trade, Industry and Energy Award at the 2023 Korea Invention Patent Exhibition.

The Korea Invention Patent Exhibition is the largest intellectual property fair in Korea, hosted by the Korean Intellectual Property Office and organized by the Korea Invention Promotion Association. Every year, it selects and exhibits outstanding domestic technologies and patented products to support commercialization. The 2023 Korea Invention Patent Exhibition is being held at COEX, Samseong-dong, Seoul, until the 4th.

The patent awarded to Neurosona this time, titled "Low-Intensity Non-Invasive Focused Ultrasound System for Deep Brain Stimulation," relates to the configuration of a low-intensity focused ultrasound system for treating patients with intractable brain diseases. The key advantage of Neurosona’s low-intensity non-invasive focused ultrasound system lies in overcoming the limitations of existing brain stimulation treatment technologies and enabling precise and safe stimulation of treatment areas in patients with intractable brain diseases.

Seonil Seo, CEO of Neurosona, said, “The intellectual property award for the non-invasive brain stimulation system using focused ultrasound technology verifies the growth potential of the electronic medicine market based on focused ultrasound technology as well as the excellence and leadership of our technology.” He added, “We will continue to secure globally differentiated competitiveness in focused ultrasound technology, create exclusive intellectual property applying advanced innovative technologies, and prove the superiority and distinctiveness of our products.”

Meanwhile, Neurosona’s “Low-Intensity Focused Ultrasound Stimulation System” was designated as an innovative medical device by the Ministry of Food and Drug Safety in August 2021, recognizing its innovative technology and clinical improvement potential. Neurosona is currently conducting clinical trials applying the “Low-Intensity Focused Ultrasound Stimulation System” to patients with various brain diseases such as depression, Alzheimer’s disease, sleep disorders, and stroke.